Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I intratumoral TDM-812 safety study in refractory breast cancer
jRCT2031200057Phase 1Suspended
- Sponsor
- 3-D Matrix
- Start
- Jun 2020
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Hydrogel Systems → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 1, open-label trial of TDM-812 in breast cancer (3 arms), sponsored by 3-D Matrix. Primary endpoints: Safety and Tolerability. Started Jun 2020; status: suspended.
02
Drugs
TDM-812
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031200057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200057.